{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000810","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.382041+00:00","generated_at":"2026-05-16T02:46:29.163260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep","bullets":["Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.","Cash and equivalents $12.1M; working capital $12.0M at Dec 31, 2025.","EB06 (anti-CXCL10) manufacturing underway for Phase 2 vitiligo study; patient enrollment targeted mid-2026.","Paridiprubart Phase 3 ARDS data under subgroup analysis; plans to present at scientific conferences.","Participating in GVFS, BIO Europe Spring, ATS 2026 and other conferences March-May 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000810","json":"https://secwatch.observer/filing/0001171843-26-000810.json","markdown":"https://secwatch.observer/filing/0001171843-26-000810.md","text":"https://secwatch.observer/filing/0001171843-26-000810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/0001171843-26-000810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/f8k_021226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:46:29.163260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}